NEW YORK, Feb. 19 /PRNewswire/ -- On November 5, 2007, under increasing government pressure, Bayer Pharmaceuticals Corporation said that it had halted worldwide sales of its drug Trasylol after a Canadian clinical study found the drug could be linked to a higher risk of death than other drugs. The Food and Drug Administration asked the company to stop selling the drug, used to prevent excessive bleeding during heart bypass surgery, pending detailed review of preliminary results from the Canadian study.
In the wake of Bayer's announcement that it was pulling its controversial heart surgery drug Trasylol from the market, nationally known plaintiff's advocates Napoli Bern & Associates, LLP commenced several litigations seeking damages for a heart patient's death. One of those litigations, arising from the death of Joseph Randone, was profiled by CBS's "60 Minutes" on Sunday, February 17, 2008. In that story, renowned medical researcher Dr. Dennis Mangano calculated that 22,000 patients could have been saved if the Food and Drug Administration removed the heart surgery drug Trasylol two years ago, when his study revealed widespread death associated with it. Dr. Mangano also told 60 Minutes correspondent Scott Pelley that Bayer, the drug's maker, failed to tell the FDA about negative results of their own Trasylol study and that the company's failure to fully apprise the FDA of their own study's findings placed the drug's success before patient well-being.
The Randone case (Josephine Randone, Executrix Of The Estate Of Joseph
Randone, And Josephine Randone, Individually, v. Bayer Corporation, et al.)
was filed by Napoli Bern & Associates, LLP, and arises from horrific post-
surgical complications suffered by Joseph Randone, a 52-year-old man who
suffered kidney failure leading to a chain reaction resulting in his death
following routine valve replacement surgery where Trasylol was utilized.
Attorney Marc Jay Bern says, "the importance of the Trasylol
|SOURCE Napoli Bern & Associates, LLP|
Copyright©2008 PR Newswire.
All rights reserved